Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 4Phase NA 2Phase 1/2 1Phase 1 1

Status

Not yet recruiting 3Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Head & Neck 6

Conditions

Nasopharyngeal Carcinoma 26Prostatic Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Nasopharyngeal Neoplasms 6Head and Neck Neoplasms 6Breast Neoplasms 5Uterine Cervical Neoplasms 4Oropharyngeal Neoplasms 3Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Tongue Neoplasms 2Salivary Gland Neoplasms 2Radiation Injuries 2Neurotoxicity Syndromes 2Hypopharyngeal Neoplasms 2Glioblastoma 2Carcinoma 2Brain Neoplasms 2Astrocytoma 2Vaginal Neoplasms 1Thoracic Neoplasms 1Stage II Prostate Adenocarcinoma AJCC v7 1Sarcoma 1Precancerous Conditions 1Postoperative Complications 1Papillomavirus Infections 1Pancreatic Intraductal Neoplasms 1Pancreatic Adenocarcinoma 1Ototoxicity 1Oligodendroglioma 1

Interventions

Gemcitabine 11Cisplatin 11Radiotherapy, Intensity-Modulated 6tislelizumab 2nimotuzumab 2camrelizumab 2Fluorouracil 2Carboplatin 2spartalizumab 1sintilimab 1sargramostim 1pembrolizumab 1fosaprepitant 1etoposide phosphate 1Tropisetron 1Radiotherapy 1Induction Chemotherapy 1Ifosfamide 1Etoposide 1Docetaxel 1Dexamethasone 1Chemotherapy, Adjuvant 1Chemoradiotherapy 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Nasopharyngeal Neoplasms × Radiotherapy, Intensity-Modulated × Clear all
NCT07524413 2026-04-13

Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 3 Not yet recruiting
514 enrolled
Head & Neck

Nasopharyngeal Neoplasms

NCT07385079 2026-02-03

Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 3 Not yet recruiting
412 enrolled
Head & Neck

Nasopharyngeal Neoplasms

NCT07373990 2026-01-28

Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 3 Not yet recruiting
418 enrolled
Head & Neck

Nasopharyngeal Neoplasms

NCT06749899 2025-05-22

QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Sun Yat-sen University

Phase 3 Recruiting
580 enrolled
Head & Neck

Nasopharyngeal Neoplasms

NCT05587374 2025-01-23

GEMSTONE

Sun Yat-sen University

Phase 3 Active not recruiting
490 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT03700476 2023-03-28

CONTINUUM

Sun Yat-sen University

Phase 3 Unknown
425 enrolled
Head & Neck

Nasopharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡